



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)  
A61K 39/395 (2006.01) A61K 31/00 (2006.01)

(21) International Application Number:

PCT/IB2015/056032

(22) International Filing Date:

7 August 2015 (07.08.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/036,382 12 August 2014 (12.08.2014) US

(71) Applicant (for all designated States except US): NO-VARTIS AG [CII/CII]; Lichtstrasse 35, 4056 Basel (CII).

(71) Applicant: DÜRR, Clemens [DE/CH]; Novartis Pharma AG, Postfach, 4002 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): BIALUCHA, Carl Uli [DE/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). COLLINS, Scott [GB/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). HU, Tiancen [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). JANATPOUR, Mary Jo [US/US]; Novartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608 (US). MEYER, Matthew John [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02319 (US).

(74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-CDII6 ANTIBODY DRUG CONJUGATES

(57) Abstract: The present invention relates to anti-CDII6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.